|
|
Office Locations:
|
1 Letterman Drive
Building D, Suite DM-900
San Francisco, CA 94129
Phone: 415-865-2050
Fax: 415-255-2048
| | |
|
|
|
- Early
- Expansion
- Growth
- Seed
|
|
|
|
Life Sciences & Healthcare
|
|
|
|
The Column Group is a venture capital firm dedicated to creating the next generation of biotechnology companies. The firm will invest in approximately 10-12 disease-focused drug discovery companies (per fund), each with the potential to become a leader in their respective field(s). Typically, Column will commit $15M to $30M per company, fostering their growth from seed and early stage to later stages of development. The Column Group will primarily focus on early stage drug discovery companies, an area currently underserved by many biotech venture capital funds. The firm is currently evaluating opportunities in the areas of cancer, inflammation, infectious disease, metabolic disorders, cardiovascular disease and nervous system disorders. TCG has $2.2 billion in assets under management.
|
|
|
|
|
|
|
Investment Firm Key
VC = Venture Capital
PE = Private Equity
A = Angel
I = Incubator
MB = Merchant Bank
VD = Venture Debt
FI = Family Investment Office
FOF = Fund of Funds
ED = Economic Development Office
TT = Technology Transfer Office
CVC = Corporate Venture Capital
SEC = Secondary Purchaser
HF = Hedge Fund/Mutual Fund
|
|
| COMPANY STAGE | REVENUE |
| Venture Capital | |
Seed Stage
(includes "pre-seed," or
concept stage) | No Revenue |
| Early Stage | Minimal
Revenue |
Growth Stage
(also called Mid-stage) | $2M-$7M |
Expansion Stage
(also called Late-stage) | $7M and greater |
| Private Equity | |
| Lower Middle Market | $10M-$249M |
| Middle Market | $250M-$499M |
| Upper Middle Market | $500M-$1B |
| Large Cap | >$1B |
|
|
|
|
|
